EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

Eli Lilly and Co.’s approval for Omvoh to treat moderate to severe Crohn’s disease in adults marks the Indianapolis company’s growing presence in the treatment of inflammatory bowel disease.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Omvoh's approval provides a new treatment option for Crohn's disease patients, especially those unresponsive to existing therapies. The FDA granted approval to Eli Lilly and Company’s ...

Eli Lilly's Q4 FY24 guidance adjustment is due to ... drivers including new product launches such as Jaypirca, Ebglyss, Omvoh and Kisunla; additional indications for existing medicines; and ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Eli Lilly's stock price finished Jan. 16 down ... On Jan. 15, the FDA approved Lilly's Omvoh for the treatment of Crohn's disease. In the Vivid-1 trial with patients who didn't respond well ...

The FDA has officially approved Eli Lilly’s drug Omvoh for adult use in moderately to severely active Crohn’s disease. Omvoh targets a specific protein called interleukin-23p19, which plays a ...

Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Omvoh ...